SCHEMBL13955487

SCHEMBL13955487

CCC(C)c1ccc(Nc2ncc(Cc3ccncc3)c3ccccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ KDR P35968 14/20 0.44
▸ FLT1 P17948 13/20 0.44
▸ PDGFRB P09619 8/20 0.44
▸ KIT P10721 7/20 0.43
▸ CSF1R P07333 2/20 0.43
▸ FLT4 P35916 2/20 0.43
▸ CIT O14578 1/20 0.43
▸ EGFR P00533 1/20 0.43
▸ HLA-A P04439 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13955571 0.90 KDR (0.48) RAB9ANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL13955411 0.85 KDR (0.48) RAB9AHPGDCYP1A2CYP2D6CYP2C9
SCHEMBL13955639 0.82 SMN1; SMN2 (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2KDR
SCHEMBL13955486 0.81 FLT1 (0.64) RAB9ANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL2201541 0.81 FLT1 (0.64) KDRFLT1PDGFRBKITCSF1R
SCHEMBL3668971 0.81 KDR (0.66) ALDH1A1SMN1; SMN2TDP1KDRFLT1
SCHEMBL13955585 0.81 KDR (0.55) RAB9ANPC1HPGDSMN1; SMN2CYP2C9
SCHEMBL13955592 0.81 CYP1A2 (0.46) ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6
SCHEMBL13955412 0.80 KDR (0.48) CYP1A2KDRFLT1PDGFRBKIT
SCHEMBL13955485 0.79 FLT1 (0.52) RAB9ATDP1KDRFLT1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1603566-B1 USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES NOVARTIS AG (CH) 2009-01-21 — — EP disclosed
Send feedback